预约演示
更新于：2026-02-01
Adefovir Dipivoxil
阿德福韦酯
更新于：2026-02-01
概要
基本信息
药物类型 小分子化药 |
别名 Adefovir di(pivaloyloxymethyl) ester、Adefovir dipivoxil (USAN)、Adefovir Pivoxil + [25] |
作用方式 抑制剂 |
作用机制 DNA polymerase抑制剂(DNA聚合酶抑制剂)、RT抑制剂(逆转录酶抑制剂) |
在研适应症 |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (2002-09-20), |
最高研发阶段(中国)临床1期 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C20H32N5O8P |
InChIKeyWOZSCQDILHKSGG-UHFFFAOYSA-N |
CAS号142340-99-6 |
关联
134
项与 阿德福韦酯 相关的临床试验CTR20251544
苯胺洛芬注射液在健康研究参与者中对转运体OAT1底物阿德福韦酯人 体药代动力学影响的临床研究
CTR20211497
评估口服FM888胶囊在中国健康成年受试者中单中心、随机、双盲、安慰剂对照、单次及多次给药、剂量递增的安全性、耐受性、药代动力学特征和食物对药代动力学影响的I期临床研究
CTR20190991
评价APL-1202片对转运体OAT1底物阿德福韦酯片人体内药代动力学影响的临床试验
100 项与 阿德福韦酯 相关的临床结果
登录后查看更多信息
100 项与 阿德福韦酯 相关的转化医学
登录后查看更多信息
100 项与 阿德福韦酯 相关的专利（医药）
登录后查看更多信息
1,518
项与 阿德福韦酯 相关的文献（医药）2026-01-25GLYCOBIOLOGY
Water-guided docking improves prediction of protein–glycan complexes
Article
作者: Rey, Esteban L ; Gamarra, Marcelo D ; Martí, Marcelo A ; Lannot, Jorge O ; Modenutti, Carlos P
Abstract:
Accurate prediction of structure of protein–carbohydrate complexes remains a significant challenge in structural glycobiology, largely due to the flexibility of glycans and the shallow, hydrophilic nature of their binding sites. To address this issue, we developed a guided docking protocol that leverages Crystallographic Water Sites (CWS) to enhance glycan pose prediction using AutoDock Vina (ADV). By defining Waters Ideal Interactions (WII)—interaction hotspots derived from water molecules in apo structures—the protocol systematically rewards chemically meaningful receptor-ligand contacts during docking simulations. The WII Guided Approach (WIIGA) was benchmarked against a curated dataset of 30 high-quality protein–oligosaccharide complexes, which included ligands ranging from tetra- to nonasaccharides. Performance evaluation demonstrated that the guided protocol consistently outperformed conventional methods (ADV, Vina Carb (VC), Vina Carb with CH–π (VC CH–π) and GlycoTorch Vina (GTV)), delivering improved pose prediction accuracy. Our method proved robust even in the absence of holo structures and was effective in cross-docking drug-like glycomimetics. The protocol is easy to implement and broadly applicable to a wide range of glycan-binding proteins. These findings underscore the value of solvent-derived information for improving docking accuracy and support the use of guided approaches as a versatile tool for glyco-ligand modeling and structure-based design.
2025-12-19MEDICINE
Adefovir dipivoxil-induced Fanconi syndrome associated with hypophosphatemic osteomalacia misdiagnosed as cervical spondylotic myelopathy: A case report and literature review
Review
作者: Ji, Jian-song ; Chen, Zhu-liu ; Zhu, Ke-jun ; Xiang, Long
Rationale::
Adefovir dipivoxil (ADV)-induced Fanconi syndrome associated with hypophosphatemic osteomalacia is an extremely rare disease. Owing to its rarity, it is easily misdiagnosed as cervical spondylotic myelopathy. Here, we present the case of a patient with Fanconi’s syndrome associated with hypophosphatemic osteomalacia that was misdiagnosed as having cervical spondylotic myelopathy.
Patient concerns::
A 44-year-old Chinese man with a 10-year history of ADV therapy for chronic hepatitis B presented with progressive bilateral lower extremity weakness for more than 6 months. Cervical magnetic resonance imaging revealed disc herniations at C4/5, C5/6, and C6/7, accompanied by spinal cord compression. Laboratory evaluations revealed glucosuria, proteinuria, hypophosphatemia, and impaired renal function. He was misdiagnosed with cervical spondylotic myelopathy and underwent anterior cervical corpectomy decompression and fusion. However, his lower limb weakness failed to improve 10 months after surgery.
Diagnosis::
On the basis of the patient’s clinical symptoms, along with his long history of oral ADV use, hypophosphatemia, and renal insufficiency, he was diagnosed with adefovir dipivoxil-induced Fanconi syndrome.
Interventions::
ADV was replaced with entecavir, and the patient was prescribed oral calcitriol 0.25 μg daily and oral calcium carbonate with vitamin D₃ (300 mg calcium and 60 IU vitamin D₃ per tablet) once daily.
Outcomes::
The patient’s lower limb muscle strength returned to normal after 6 months.
Lessons::
Fanconi syndrome with hypophosphatemic osteomalacia induced by low-dose adefovir dipivoxil (10 mg/d) is extremely rare. The condition may present with pain, muscle weakness, or numbness, and its nonspecific manifestations can easily lead to a misdiagnosis of cervical spondylotic myelopathy. For patients receiving long-term ADV therapy who develop such symptoms, especially in the presence of cervical disc herniation with spinal cord compression, clinicians should carefully evaluate laboratory findings and physical examination results to exclude the possibility of ADV-induced Fanconi syndrome.
2025-12-01Transplantation and Cellular Therapy
Letermovir Prophylaxis Does Not Hinder Immune Reconstitution While Reshaping Viral Infection Landscape in Children
Article
作者: Saglio, Francesco ; Faraci, Maura ; Nucera, Silvia ; Ceolin, Valeria ; Apolito, Vincenzo ; Dagliano, Francesca ; Menconi, Mariacristina ; Balduzzi, Adriana ; Fagioli, Franca ; Romani, Francesca ; Carzaniga, Viola ; Gottardi, Francesca ; Masetti, Riccardo ; Spadea, Manuela ; Baccelli, Francesco ; Gangi, Alessandro Di ; Vitale, Raffaele ; Tomatis, Alessio
BACKGROUND:
Letermovir prophylaxis in adults reduces CMV-related morbidity and mortality and may delay T-cell recovery. Pediatric data are limited.
OBJECTIVES:
We aimed to compare absolute counts of CD3⁺, CD3⁺CD4⁺, CD3⁺CD8⁺, CD19⁺, CD3-CD16⁺CD56⁺ cells on days +60 and +100 after allo-HCT in children managed with pre-emptive therapy (PET) versus those receiving letermovir prophylaxis (LET). Secondary aims were to compare viral outcomes (CMV, EBV, ADV, HHV-6, parvovirus B19, HSV, VZV), within the first 180 days post-HCT in the 2 cohorts.
STUDY DESIGN:
Retrospective, multicenter study, using propensity score matching to compare letermovir prophylaxis (LET, n = 81) with pre-emptive therapy (PET, n = 81) in children receiving allo-HCT. CD3⁺, CD3⁺CD4⁺, CD3⁺CD8⁺, CD19⁺, CD3-CD16+CD56⁺ counts on days +60, +100 were measured by flow cytometry. Virological outcomes (CMV, EBV, ADV, HHV-6, parvovirus B19, HSV, VZV) were reported up to day +180.
RESULTS:
Immune recovery was comparable in both cohorts at each landmark. LET significantly decreased the total number of viral events (45/115 versus 70/115, P = .024), day-90 cumulative incidence of CMV infection (11.1% versus 42%; P < .001), without increasing that of EBV (11.1% versus 18.5%; P = .2). ADV prevailed in LET patients (8 versus 0, P = .006). Viral diseases occurred later under LET (median 58 versus 30 days; P = .018), including 2 EBV-related post-transplant lymphoproliferative disorders (EBV-PTLD), without CMV-disease. Multiple infections were halved (5 versus 17 patients, P = .01).
CONCLUSIONS:
These data show that letermovir does not influence lymphoid reconstitution while markedly reducing CMV burden and reshaping the pediatric post-transplant virological landscape (more ADV and a potential signal for EBV-PTLD).
100 项与 阿德福韦酯 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 乙型肝炎 | 中国 | 2005-03-23 | |
| 慢性乙型肝炎 | 美国 | 2002-09-20 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性肝炎 | 临床3期 | 美国 | 2007-08-01 | |
| 慢性肝炎 | 临床3期 | 中国 | 2007-08-01 | |
| 慢性肝炎 | 临床3期 | 阿根廷 | 2007-08-01 | |
| 慢性肝炎 | 临床3期 | 澳大利亚 | 2007-08-01 | |
| 慢性肝炎 | 临床3期 | 巴西 | 2007-08-01 | |
| 慢性肝炎 | 临床3期 | 加拿大 | 2007-08-01 | |
| 慢性肝炎 | 临床3期 | 希腊 | 2007-08-01 | |
| 慢性肝炎 | 临床3期 | 西班牙 | 2007-08-01 | |
| 慢性肝炎 | 临床3期 | 中国台湾 | 2007-08-01 | |
| 慢性肝炎 | 临床3期 | 泰国 | 2007-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 104 | 蓋襯艱範憲壓鏇顧窪齋(範艱網願膚選膚範願選) = 廠製膚糧齋齋廠鹽構艱 餘遞獵構築餘鹹願鏇廠 (構膚鬱艱蓋範窪憲夢遞, 1.50) 更多 | - | 2018-03-26 | |||
临床1/2期 | 16 | 遞鏇夢壓製觸夢蓋蓋鏇 = 餘壓鬱選壓選鹹窪範窪 選製構夢鑰廠願網繭簾 (憲顧顧獵製齋蓋憲糧願, 願襯鹹鏇窪築獵範願築 ~ 網顧憲鑰遞蓋淵選積簾) 更多 | - | 2017-03-15 | |||
临床4期 | 280 | Peg-IFN-Alfa-2a+Adefovir (Peg-IFN-Alfa-2a + Adefovir) | 壓襯艱鑰膚膚遞簾選艱 = 觸構壓鏇鹽鬱蓋夢膚夢 範鹹積簾糧積獵壓繭艱 (膚顧獵夢顧淵衊鹽構齋, 構膚齋網獵積襯網蓋積 ~ 願製繭範獵鏇齋願鹽範) 更多 | - | 2015-11-20 | ||
(Peg-IFN-Alfa-2a + Entecavir) | 壓襯艱鑰膚膚遞簾選艱 = 憲壓範觸糧觸壓願鬱觸 範鹹積簾糧積獵壓繭艱 (膚顧獵夢顧淵衊鹽構齋, 遞鑰糧壓廠夢遞願壓鹽 ~ 蓋製鏇糧鹽顧築醖築鏇) 更多 | ||||||
临床4期 | 90 | 築餘淵選鹹醖鏇鬱觸餘 = 簾願窪鏇壓鏇構繭築夢 鏇窪壓製觸鹹窪餘醖鏇 (繭構製鹽積夢壓鹹製願, 築鹹構構遞範鹹製獵衊 ~ 網繭繭醖壓窪築鬱鹽憲) 更多 | - | 2014-01-13 | |||
(Adefovir Plus Lamivudine) | 築餘淵選鹹醖鏇鬱觸餘 = 糧鹹鏇窪蓋餘願餘遞淵 鏇窪壓製觸鹹窪餘醖鏇 (繭構製鹽積夢壓鹹製願, 憲網鬱網醖遞構簾願範 ~ 選襯齋積糧廠鹹齋淵繭) 更多 | ||||||
临床3期 | 173 | (Adefovir Dipivoxil (ADV)) | 選製鬱窪鏇選壓築壓夢 = 選淵築膚餘餘簾鹹構夢 製觸觸築壓夢淵遞範糧 (淵膚獵襯鏇衊選鬱膚廠, 襯遞壓窪襯製鹹糧觸鹹 ~ 齋膚膚壓衊衊鏇鏇廠膚) 更多 | - | 2011-06-03 | ||
Placebo (PLB)+Lamivudine (Placebo (PLB)) | 選製鬱窪鏇選壓築壓夢 = 膚積淵繭醖襯餘淵窪醖 製觸觸築壓夢淵遞範糧 (淵膚獵襯鏇衊選鬱膚廠, 築襯製獵積醖繭艱獵廠 ~ 簾獵鹽鏇蓋夢願壓鏇積) 更多 | ||||||
临床4期 | 155 | 衊糧鹽構衊範壓壓觸鑰 = 壓構構積網膚窪遞網顧 構廠願範艱憲糧襯顧築 (糧壓窪廠壓衊艱範鑰廠, 範艱膚鹹遞廠簾獵蓋夢 ~ 願構網鏇選範糧齋壓壓) 更多 | - | 2010-10-15 | |||
临床3期 | 105 | LAM group | 壓餘餘遞築製鬱艱壓積(膚遞願糧顧觸鬱鑰獵襯) = 膚網艱衊鹽遞網網遞蓋 遞糧構壓醖觸夢蓋餘艱 (衊鑰艱製餘鑰鏇壓鬱獵, 1.896) 更多 | - | 2009-08-03 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用